Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. Prat A, et al. J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042. J Natl Cancer Inst. 2020. PMID: 31037288 Free PMC article.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E, Prat A. Brasó-Maristany F, et al. Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3. Nat Commun. 2020. PMID: 31959756 Free PMC article. Clinical Trial.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martinez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A. Schettini F, et al. Cancer Treat Rev. 2020 Mar;84:101965. doi: 10.1016/j.ctrv.2020.101965. Epub 2020 Jan 17. Cancer Treat Rev. 2020. PMID: 32000054 Free PMC article.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Gris-Oliver A, et al. Clin Cancer Res. 2020 Jul 15;26(14):3720-3731. doi: 10.1158/1078-0432.CCR-19-3324. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220884 Free PMC article.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, Rodríguez A, Martínez D, Galván P, Rodríguez AB, Martinez A, Muñoz M, Prat A. Martínez-Sáez O, et al. Breast Cancer Res. 2020 May 13;22(1):45. doi: 10.1186/s13058-020-01284-9. Breast Cancer Res. 2020. PMID: 32404150 Free PMC article.
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, Burgués O, Albanell J, Rojo F, Lluch A, de Dueñas EM, Rosen JM, Johnson GL, Carey LA, Prat A, Perou CM. Garcia-Recio S, et al. J Clin Invest. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. J Clin Invest. 2020. PMID: 32573490 Free PMC article.
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. Griguolo G, et al. Cancers (Basel). 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. Cancers (Basel). 2020. PMID: 32674482 Free PMC article.
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS. Prat A, et al. Clin Cancer Res. 2020 Dec 1;26(23):6141-6148. doi: 10.1158/1078-0432.CCR-20-2793. Epub 2020 Sep 22. Clin Cancer Res. 2020. PMID: 32962980 Clinical Trial.
52 results